Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CD103+ cells at the forefront of anticancer immunity.

Literature DB >> 29147613

CD103⁺ cells at the forefront of anticancer immunity.

Claire Vanpouille-Box¹, Lorenzo Galluzzi^1,2,3.

Abstract

Entities: Gene

Keywords: BATF3; PD-1; PD-L1; cytotoxic T lymphocytes; dendritic cells; immune checkpoint blockers

Year: 2017 PMID： 29147613 PMCID： PMC5674943 DOI： 10.1080/2162402X.2017.1356154

Source DB: PubMed Journal: Oncoimmunology ISSN： 2162-4011 Impact factor: 8.110

× No keyword cloud information.

16 in total

Review 1. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Authors: Jonathan Pol; Erika Vacchelli; Fernando Aranda; Francesca Castoldi; Alexander Eggermont; Isabelle Cremer; Catherine Sautès-Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2015-03-02 Impact factor: 8.110

Review 2. Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors: Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal: Oncoimmunology Date: 2016-07-25 Impact factor: 8.110

Review 3. Immunogenic cell death in cancer and infectious disease.

Authors: Lorenzo Galluzzi; Aitziber Buqué; Oliver Kepp; Laurence Zitvogel; Guido Kroemer
Journal: Nat Rev Immunol Date: 2016-10-17 Impact factor: 53.106

4. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Authors: Bernhard Mlecnik; Gabriela Bindea; Helen K Angell; Pauline Maby; Mihaela Angelova; David Tougeron; Sarah E Church; Lucie Lafontaine; Maria Fischer; Tessa Fredriksen; Maristella Sasso; Amélie M Bilocq; Amos Kirilovsky; Anna C Obenauf; Mohamad Hamieh; Anne Berger; Patrick Bruneval; Jean-Jacques Tuech; Jean-Christophe Sabourin; Florence Le Pessot; Jacques Mauillon; Arash Rafii; Pierre Laurent-Puig; Michael R Speicher; Zlatko Trajanoski; Pierre Michel; Richard Sesboüe; Thierry Frebourg; Franck Pagès; Viia Valge-Archer; Jean-Baptiste Latouche; Jérôme Galon
Journal: Immunity Date: 2016-03-15 Impact factor: 31.745

Review 5. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors: Padmanee Sharma; James P Allison
Journal: Cell Date: 2015-04-09 Impact factor: 41.582

Review 6. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

Authors: Mizuki Nishino; Nikhil H Ramaiya; Hiroto Hatabu; F Stephen Hodi
Journal: Nat Rev Clin Oncol Date: 2017-06-27 Impact factor: 66.675

7. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

Authors: Edward W Roberts; Miranda L Broz; Mikhail Binnewies; Mark B Headley; Amanda E Nelson; Denise M Wolf; Tsuneyasu Kaisho; Dusan Bogunovic; Nina Bhardwaj; Matthew F Krummel
Journal: Cancer Cell Date: 2016-07-14 Impact factor: 31.743

Review 8. Cancer classification using the Immunoscore: a worldwide task force.

Authors: Jérôme Galon; Franck Pagès; Francesco M Marincola; Helen K Angell; Magdalena Thurin; Alessandro Lugli; Inti Zlobec; Anne Berger; Carlo Bifulco; Gerardo Botti; Fabiana Tatangelo; Cedrik M Britten; Sebastian Kreiter; Lotfi Chouchane; Paolo Delrio; Hartmann Arndt; Martin Asslaber; Michele Maio; Giuseppe V Masucci; Martin Mihm; Fernando Vidal-Vanaclocha; James P Allison; Sacha Gnjatic; Leif Hakansson; Christoph Huber; Harpreet Singh-Jasuja; Christian Ottensmeier; Heinz Zwierzina; Luigi Laghi; Fabio Grizzi; Pamela S Ohashi; Patricia A Shaw; Blaise A Clarke; Bradly G Wouters; Yutaka Kawakami; Shoichi Hazama; Kiyotaka Okuno; Ena Wang; Jill O'Donnell-Tormey; Christine Lagorce; Graham Pawelec; Michael I Nishimura; Robert Hawkins; Réjean Lapointe; Andreas Lundqvist; Samir N Khleif; Shuji Ogino; Peter Gibbs; Paul Waring; Noriyuki Sato; Toshihiko Torigoe; Kyogo Itoh; Prabhu S Patel; Shilin N Shukla; Richard Palmqvist; Iris D Nagtegaal; Yili Wang; Corrado D'Arrigo; Scott Kopetz; Frank A Sinicrope; Giorgio Trinchieri; Thomas F Gajewski; Paolo A Ascierto; Bernard A Fox
Journal: J Transl Med Date: 2012-10-03 Impact factor: 5.531

9. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.

Authors: Kai Hildner; Brian T Edelson; Whitney E Purtha; Mark Diamond; Hirokazu Matsushita; Masako Kohyama; Boris Calderon; Barbara U Schraml; Emil R Unanue; Michael S Diamond; Robert D Schreiber; Theresa L Murphy; Kenneth M Murphy
Journal: Science Date: 2008-11-14 Impact factor: 47.728

10. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

Authors: Zachary A Cooper; Alexandre Reuben; Christine N Spencer; Peter A Prieto; Jacob L Austin-Breneman; Hong Jiang; Cara Haymaker; Vancheswaran Gopalakrishnan; Michael T Tetzlaff; Dennie T Frederick; Ryan J Sullivan; Rodabe N Amaria; Sapna P Patel; Patrick Hwu; Scott E Woodman; Isabella C Glitza; Adi Diab; Luis M Vence; Jaime Rodriguez-Canales; Edwin R Parra; Ignacio I Wistuba; Lisa M Coussens; Arlene H Sharpe; Keith T Flaherty; Jeffrey E Gershenwald; Lynda Chin; Michael A Davies; Karen Clise-Dwyer; James P Allison; Padmanee Sharma; Jennifer A Wargo
Journal: Oncoimmunology Date: 2016-02-02 Impact factor: 8.110

3 in total

CD103⁺ cells at the forefront of anticancer immunity.

Review 1. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Review 2. Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Review 3. Immunogenic cell death in cancer and infectious disease.

4. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Review 5. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Review 6. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

7. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

Review 8. Cancer classification using the Immunoscore: a worldwide task force.

9. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.

10. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

1. Batf3⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Review 2. Trial watch: dendritic cell vaccination for cancer immunotherapy.

Review 3. A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers.

CD103+ cells at the forefront of anticancer immunity.

Review 1. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Review 2. Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Review 3. Immunogenic cell death in cancer and infectious disease.

4. Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability.

Review 5. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Review 6. Monitoring immune-checkpoint blockade: response evaluation and biomarker development.

7. Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.

Review 8. Cancer classification using the Immunoscore: a worldwide task force.

9. Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity.

10. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma.

1. Batf3+ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.

Review 2. Trial watch: dendritic cell vaccination for cancer immunotherapy.

Review 3. A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers.

CD103⁺ cells at the forefront of anticancer immunity.

1. Batf3⁺ DCs and type I IFN are critical for the efficacy of neoadjuvant cancer immunotherapy.